Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Wollner · SciRah

Researcher profile · Semantic Scholar

M. Wollner

Share profile

M. Wollner — researcher profile on SciRah

h-index: 19
Works: 69
Citations: 2,260

Most-cited papers

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
C. Rudin, M. Awad, A. Navarro, M. Gottfried +16 more
2020Journal of Clinical Oncology621 citations Open access
Semantic Scholar
Cancer Recurrence: Diagnostic Value and Impact on Patient Management
Z. Keidar, N. Haim, L. Guralnik, M. Wollner +3 more
2004215 citations
Semantic Scholar
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check‐Point Inhibitors
E. Dudnik, N. Peled, H. Nechushtan, M. Wollner +15 more
2018Journal of Thoracic Oncology197 citations
Semantic Scholar
Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies.
T. Taha, D. Meiri, S. Talhamy, M. Wollner +2 more
2019The Oncologist142 citations Open access
Semantic Scholar
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome
G. Bar-Sela, Idan Cohen, S. Campisi-Pinto, G. Lewitus +9 more
2020Cancers119 citations Open access
Semantic Scholar
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
E. Dudnik, M. Moskovitz, S. Daher, S. Shamai +15 more
2017Lung Cancer105 citations
Semantic Scholar
ALK‐Rearranged Non–Small‐Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism
A. Zer, M. Moskovitz, D. Hwang, A. Hershko-Klement +12 more
2017Clinical Lung Cancer97 citations
Semantic Scholar
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
M. Schuler, R. Berardi, W. Lim, M. D. de Jonge +15 more
2020Annals of Oncology93 citations Open access
Semantic Scholar
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.
B. Besse, E. Felip, R. Campelo, M. Cobo +64 more
2023Annals of Oncology76 citations Open access
Semantic Scholar
Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
G. Bar-Sela, M. Wollner, L. Hammer, A. Agbarya +2 more
2013European Journal of Cancer66 citations
Semantic Scholar
Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).
M. Schuler, R. Berardi, W. Lim, R. van Geel +16 more
201658 citations
Semantic Scholar
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
R. Cornelissen, A. Prelaj, Sophie Sun, C. Baik +12 more
2023Journal of Thoracic Oncology53 citations Open access
Semantic Scholar
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
E. Dudnik, S. Kareff, M. Moskovitz, Chul Kim +9 more
2021Journal for ImmunoTherapy of Cancer48 citations Open access
Semantic Scholar
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing
A. Schrock, G. Frampton, D. Herndon, J. Greenbowe +20 more
2016Clinical Cancer Research43 citations Open access
Semantic Scholar
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
E. Dudnik, M. Moskovitz, Y. Rottenberg, A. Lobachov +9 more
2021Oncoimmunology41 citations Open access
Semantic Scholar
Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.
I. Turgeman, M. Wollner, G. Hassoun, L. Bonstein +1 more
2017Anti-Cancer Drugs38 citations
Semantic Scholar
Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors
I. Finkel, M. Sternschuss, M. Wollner, S. Shamai +4 more
2019Journal of immunotherapy26 citations
Semantic Scholar
KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
C. Rudin, M. Awad, A. Navarro, M. Gottfried +16 more
202022 citations
Semantic Scholar
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.
L. Holtzman, M. Moskovitz, D. Urban, H. Nechushtan +9 more
2021Clinical Lung Cancer21 citations
Semantic Scholar
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
K. Oselin, B. Shim, M. Okada, M. Bryl +16 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.
C. Rudin, H. R. Kim, A. Navarro, M. Gottfried +16 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
E. Dudnik, J. Bar, N. Peled, Elias Bshara +17 more
2019Clinical Lung Cancer15 citations
Semantic Scholar
Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature
M. Moskovitz, M. Wollner, N. Haim
2015Case Reports in Oncological Medicine15 citations Open access
Semantic Scholar
MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC: Topic: Medical Oncology
T. Bauer, M. Schuler, R. Berardi, W. Lim +16 more
2016Journal of Thoracic Oncology11 citations Open access
Semantic Scholar
Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447
G. Bar-Sela, Idan Cohen, S. Campisi-Pinto, G. Lewitus +9 more
2022Cancers10 citations Open access
Semantic Scholar
LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
R. Cornelissen, Shawn W. Sun, M. Wollner, M. Garassino +9 more
2021Annals of Oncology10 citations Open access
Semantic Scholar
The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study.
S. S. Shachar, G. Bar-Sela, A. Peer, M. Moskovitz +6 more
2022Journal of Geriatric Oncology9 citations
Semantic Scholar
Vitamin D deficiency in oncology patients--an ignored condition: impact on hypocalcemia and quality of life.
E. Segal, S. Felder, N. Haim, Hedva Yoffe-Sheinman +4 more
2012The Israel Medical Association journal : IMAJ9 citations
Semantic Scholar
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
H. R. Kim, M. Awad, A. Navarro, M. Gottfried +16 more
2023JTO Clinical and Research Reports8 citations Open access
Semantic Scholar
Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo).
S. S. Shachar, Rachel S. Fried, I. Shafran, M. Moskovitz +4 more
20188 citations
Semantic Scholar
144P Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO)
S. Daher, A. Allen, Y. Rottenberg, H. Nasrallah +8 more
2022Annals of Oncology7 citations Open access
Semantic Scholar
MA 02.06 BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy
E. Dudnik, N. Peled, M. Wollner, A. Onn +8 more
20177 citations Open access
Semantic Scholar
Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
A. Agbarya, M. Melamed-Frank, O. Kaidar-Person, Ilana Goldberg-Cohen +5 more
2014SpringerPlus7 citations Open access
Semantic Scholar
Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin
N. Haim, E. Rosenblatt, M. Wollner, M. Ben-Shahar +2 more
2004Cancer Chemotherapy and Pharmacology5 citations
Semantic Scholar
1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
H. Kim, M. Awad, A. Navarro, M. Gottfried +16 more
20204 citations Open access
Semantic Scholar
Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study.
K. Shulman, N. Haim, M. Wollner, Z. Bernstein +2 more
2012Oncology Letters4 citations Open access
Semantic Scholar
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
M. Moskovitz, E. Dudnik, S. Shamai, Y. Rotenberg +12 more
2022The Oncologist3 citations Open access
Semantic Scholar
150P Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study
M. Gottfried, S. Rosenberg, J. Dudnik, M. Wollner +4 more
20183 citations Open access
Semantic Scholar
Small cell lung cancer and other thoracic malignancies
H. Daga, H. Murakami, N. Yamamoto, T. Shibata +202 more
20123 citations Open access
Semantic Scholar
OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data
E. Dudnik, M. Moskovitz, A. Agbarya, T. Kuznetsov +7 more
2019Journal of Thoracic Oncology2 citations Open access
Semantic Scholar
Anti‐PD‐1 antibodies in non‐small cell lung cancer (NSCLC): The real‐life setting experience: 181P
E. Dudnik, M. Moskovitz, M. Wollner, A. Zer +6 more
2016Journal of Thoracic Oncology2 citations Open access
Semantic Scholar
Lower lung cancer rates in Jewish smokers in Israel and the USA
G. Rennert, R. Kremer, H. Rennert, M. Wollner +5 more
2015International Journal of Cancer2 citations Open access
Semantic Scholar
Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma.
G. Bar-Sela, M. Tsalic, M. Steiner, M. Wollner +1 more
2009Anticancer Research2 citations
Semantic Scholar
FP12.02 Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers
L. Holtzman, M. Moskovitz, D. Urban, M. Wollner +7 more
2021Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
The association between geriatric assessment, body composition measures, and treatment-related toxicity in elderly cancer patients: A prospective cohort study.
S. S. Shachar, G. Bar-Sela, A. Peer, M. Moskovitz +5 more
2021Journal of Clinical Oncology1 citations
Semantic Scholar
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence
E. Dudnik, M. Moskovitz, A. Agbarya, T. Gottfried +9 more
2020International Journal of Cancer1 citations Open access
Semantic Scholar
1324P Pembrolizumab as a monotherapy (P) or in combination with platinum-based chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumour proportion score (TPS) ≥50%: A real-world data (Israeli Lung Cancer Group)
E. Dudnik, M. Moskovitz, Y. Rottenberg, A. Lobachov +8 more
20201 citations Open access
Semantic Scholar
Mistletoe as complementary treatment in patients with advanced non-small cell lung cancer treated with carboplatin-based combinations: A randomized phase II study.
G. Bar-Sela, M. Wollner, L. Hammer, A. Agbarya +2 more
20121 citations
Semantic Scholar
65P DOES PET-CT BASED CLINICAL STAGING OF NON-SMALL CELL LUNG CANCER OBVIATE INVASIVE PROCEDURES?
D. Faber, R. Kremer, M. Orlovsky, M. Lapidot +6 more
20111 citations
Semantic Scholar
3044 Mistletoe as complementary treatment in patients with advanced non- small-cell lung cancer (NSCLC) treated with carboplatin/gemcitabine combination: a randomized phase II study
G. Bar-Sela, M. Wollner, A. Agbarya, L. Zwergel +4 more
20091 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Moskovitz×20
Invite
M. Moskovitz — researcher profile on SciRah
E. Dudnik×16
Invite
E. Dudnik — researcher profile on SciRah
A. Zer×15
Invite
A. Zer — researcher profile on SciRah
J. Bar×13
Invite
J. Bar — researcher profile on SciRah

×11

Invite

M. Gottfried — researcher profile on SciRah

Invite

N. Peled — researcher profile on SciRah

Invite

T. Shochat — researcher profile on SciRah

Invite

A. Agbarya — researcher profile on SciRah

G. Bar-Sela×10

Invite

G. Bar-Sela — researcher profile on SciRah

Invite

N. Haim — researcher profile on SciRah

H. Nechushtan×9

Invite

H. Nechushtan — researcher profile on SciRah

Invite

D. Urban — researcher profile on SciRah